WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has received the expected notification from the NASDAQ Listing Qualifications Department that the Company has not regained compliance since being notified on August 17, 2007 that the market value of its common shares was below the $50 million requirement for continued listing on The NASDAQ Global Market according to Marketplace Rule 4450(b)(1)(A). Pursuant to NASDAQ rules, the Company plans to request a hearing before a NASDAQ Listing Qualifications Panel. At the hearing, the Company will request continued listing on The NASDAQ Global Market pending completion of its plan to demonstrate compliance. The Company’s securities will remain listed on The NASDAQ Global Market throughout the hearing process.
